Related Experiment Videos
[Clinical studies on cefozopran in pediatrics]
Insights
Cefozopran (CZOP) demonstrated 100% efficacy in treating pediatric bacterial infections, eradicating all tested pathogens. This antibiotic shows promise for treating serious childhood infections with minimal adverse effects.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Bacteriology
Background:
- Pediatric bacterial infections pose significant health risks.
- Effective antibiotic treatment is crucial for favorable outcomes.
- Cefozopran (CZOP) is a third-generation cephalosporin with broad-spectrum activity.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Cefozopran (CZOP) in pediatric patients.
- To assess the bacteriological eradication rates of pathogens in children treated with CZOP.
- To determine the incidence of adverse events associated with CZOP administration in pediatric populations.
Main Methods:
- Intravenous administration of Cefozopran (CZOP) to 9 pediatric patients (1 month to 13 years).
- Dose range: 56.7–200 mg/kg/day, divided into 3 or 4 doses.
- Clinical and bacteriological assessments were performed on patients with various bacterial infections.
Main Results:
- Overall clinical efficacy rate of 100% (6 excellent, 2 good) in 8 evaluated patients.
- Bacteriological eradication of all 5 pathogen strains (Haemophilus influenzae, Staphylococcus aureus, Escherichia coli).
- Adverse events observed in 4 cases: wheal (1), elevated GOT/GPT (2), eosinophilia (1).
Conclusions:
- Cefozopran (CZOP) is highly effective for treating pediatric bacterial infections.
- The drug demonstrated excellent bacteriological eradication of common pediatric pathogens.
- CZOP appears to be a safe and effective therapeutic option for children with bacterial infections.
Abstract:
Cefozopran (CZOP) was administered via intravenous injection to 9 patients (ages ranging from 1 month to 13 years) with pediatric bacterial infections, at daily dose levels between 56.7 and 200 mg/kg, divided into 3 or 4 doses. The following results were obtained. 1. Eight patients, including 1 with purulent meningitis, 1 with sepsis, 3 with acute pneumonia and 3 with lymphadenitis, were treated and subjected to clinical evaluation. Clinical effects were excellent in 6 cases and good in 2, with an overall efficacy rate of 100%. One case with pyoderma was not evaluated because of a combined use of an external antibiotic. 2. Organisms suspected as pathogens included 5 strains: 3 strains of Haemophilus influenzae, 1 strain of Staphylococcus aureus and 1 of Escherichia coli. Bacteriologically, all the strains were eradicated. 3. Side effects or abnormal laboratory test results were observed in 4 cases; wheal in 1 case, elevated GOT and GPT in 2 cases and eosinophilia in 1 case. 4. From the results described above, we considered that CZOP would be an effective drug for use in pediatric bacterial infections.